The United States stands as a global outlier when it comes to childhood vaccinations, recommending immunizations against a whopping 18 diseases — significantly more than other developed nations. This stark contrast has prompted new scrutiny of America’s approach to pediatric immunization protocols.
As of January 2025, U.S. health authorities recommend vaccinating all children against 18 different diseases, including COVID-19. That number puts America well ahead of peer countries like Denmark, which targets just 10 diseases with “serious morbidity or mortality risks,” Japan with 14, and Germany with 15.
International Disparities
The differences don’t stop at the number of vaccines. The complexity of the U.S. schedule also stands out, particularly regarding COVID-19 vaccinations for children. The CDC’s 2025 guidelines outline multiple dose regimens of Pfizer-BioNTech, Moderna, and Novavax vaccines for children as young as five, with intricate timing specifications that many parents find challenging to navigate.
“In January 2025, the United States recommended vaccinating all children for 18 diseases, including COVID-19, making our country a high outlier in the number of vaccinations recommended for all children,” notes a recent health policy memorandum addressing these disparities.
Why such differences between countries with similar resources and healthcare capabilities? That’s a question now formally being asked at the highest levels of U.S. health policy.
Reviewing the Evidence
The memorandum directs both the Secretary of Health and Human Services and the CDC Director to conduct a thorough review comparing U.S. practices with international standards. Specifically, they must examine “best practices from peer, developed countries for core childhood vaccination recommendations” and the scientific evidence behind those approaches.
If this review determines that international approaches are “superior to current domestic recommendations,” officials are instructed to update the U.S. childhood vaccine schedule accordingly, while still “preserving access to vaccines currently available to Americans,” according to the document.
The directive represents a significant shift in how American health authorities might approach childhood vaccination policies. But it’s careful to note that it “does not create any right or benefit, substantive or procedural, enforceable at law or in equity” against the government or its officials.
For parents navigating the current CDC schedule, the complexity can be daunting. Take the COVID-19 recommendations alone: children aged 5-11 may receive “3 or more doses Pfizer-BioNTech” with specific timing requirements, or alternative regimens involving Moderna vaccines with different dosing intervals. For unvaccinated children, separate protocols exist, further complicating the picture.
This level of detail contrasts sharply with the more streamlined approaches seen in countries like Denmark, where vaccination schedules target fewer diseases with simpler protocols.
Looking Forward
The outcome of this review could potentially reshape how American children receive immunizations for years to come. If U.S. health authorities determine that the Danish, Japanese, or German approaches better serve public health goals with stronger scientific backing, American families might see a simplified vaccination schedule in the future.
For now, the current recommendations remain in place as the review process begins. The question that remains is whether America’s exceptional position on childhood vaccinations represents the gold standard in preventive care or an approach due for recalibration based on international best practices.
